GB981242A - Vaccines containing rare earth salts - Google Patents
Vaccines containing rare earth saltsInfo
- Publication number
- GB981242A GB981242A GB3762061A GB3762061A GB981242A GB 981242 A GB981242 A GB 981242A GB 3762061 A GB3762061 A GB 3762061A GB 3762061 A GB3762061 A GB 3762061A GB 981242 A GB981242 A GB 981242A
- Authority
- GB
- United Kingdom
- Prior art keywords
- rare earth
- vaccine
- earth cation
- vaccines
- braxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title abstract 9
- 229910052761 rare earth metal Inorganic materials 0.000 title abstract 5
- -1 rare earth salts Chemical class 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000003734 kidney Anatomy 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 150000000703 Cerium Chemical class 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229910052746 lanthanum Inorganic materials 0.000 abstract 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The antigenicity of vaccines containing antigenic material of microbial origin is enhanced by mixing with the vaccine a salt containing a rare earth cation associated with an immunologically acceptable anion. A concentration between about 2 g. and about 0.008 g. of the rare earth cation is employed per 100 ml. of vaccine. Preferably, an aqueous solution of a water-soluble salt of the rare earth cation is added to the vaccine, but the vaccine may be added to a water-insoluble salt of the rare earth cation. Lanthanum and cerium salts may be used, particularly the acetate. Vaccines specified are Pulpy kidney, Braxy, Blackleg, Braxy-blackleg-pulpy kidney and a seven valent vaccine for diseases of the sheep. The invention also relates to the treatment of diseases in animals due to pathogenic microbes by the parenteral administration of the above vaccines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3762061A GB981242A (en) | 1961-10-19 | 1961-10-19 | Vaccines containing rare earth salts |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3762061A GB981242A (en) | 1961-10-19 | 1961-10-19 | Vaccines containing rare earth salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB981242A true GB981242A (en) | 1965-01-20 |
Family
ID=10397783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB3762061A Expired GB981242A (en) | 1961-10-19 | 1961-10-19 | Vaccines containing rare earth salts |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB981242A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3522347A (en) * | 1968-01-25 | 1970-07-28 | American Cyanamid Co | Toxoid compositions |
| EP0232717A3 (en) * | 1986-01-10 | 1989-02-15 | Shiosaka Sadao | Antibody specific to low-molecular weight substance and method of producing the same by using colloidal metal particles as carrier |
| US5656298A (en) * | 1992-09-25 | 1997-08-12 | Dynagen, Inc. | Immunobooster for delayed release of immunogen |
| US6528051B2 (en) | 1997-11-10 | 2003-03-04 | Cytimmune Sciences, Inc. | Methods and compositions for enhancing immune response |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US7951614B2 (en) | 2003-12-02 | 2011-05-31 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US7960145B2 (en) | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US8137989B2 (en) | 1994-03-18 | 2012-03-20 | Cytimmune Sciences, Inc. | Method for delivering a cytokine using a colloidal metal |
-
1961
- 1961-10-19 GB GB3762061A patent/GB981242A/en not_active Expired
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3522347A (en) * | 1968-01-25 | 1970-07-28 | American Cyanamid Co | Toxoid compositions |
| EP0232717A3 (en) * | 1986-01-10 | 1989-02-15 | Shiosaka Sadao | Antibody specific to low-molecular weight substance and method of producing the same by using colloidal metal particles as carrier |
| US5112606A (en) * | 1986-01-10 | 1992-05-12 | Sadao Shiosaka | Method of producing antibodies using colloidal metal as carrier |
| US5656298A (en) * | 1992-09-25 | 1997-08-12 | Dynagen, Inc. | Immunobooster for delayed release of immunogen |
| US8137989B2 (en) | 1994-03-18 | 2012-03-20 | Cytimmune Sciences, Inc. | Method for delivering a cytokine using a colloidal metal |
| US7387900B2 (en) | 1997-11-10 | 2008-06-17 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US7790167B2 (en) | 1997-11-10 | 2010-09-07 | Cyt Immune Sciences, Inc. | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US6528051B2 (en) | 1997-11-10 | 2003-03-04 | Cytimmune Sciences, Inc. | Methods and compositions for enhancing immune response |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| USRE42524E1 (en) | 2001-04-30 | 2011-07-05 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US8785202B2 (en) | 2001-04-30 | 2014-07-22 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US7951614B2 (en) | 2003-12-02 | 2011-05-31 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US7960145B2 (en) | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US8486663B2 (en) | 2007-11-08 | 2013-07-16 | Cytlmmune Sciences, Inc. | Compositions and methods for generating antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ainsworth et al. | Effect of microbial antigens on irradiation mortality in mice. | |
| GB981242A (en) | Vaccines containing rare earth salts | |
| GB1256456A (en) | Ethylethyleneimine as inactivating agent in antigen-containing pharmaceutical preparations | |
| GB1037950A (en) | Acidic aqueous iodine concentrates | |
| ES446637A1 (en) | PROCEDURE FOR THE PREPARATION OF ACELLULAR VACCINES. | |
| US3422188A (en) | Tissue culture hog cholera vaccine | |
| Cunningham | Parenteral administration of copper to sheep | |
| Kenner et al. | Cetyl Pyridinium Chloride: II. An In Vivo Method of Evaluation | |
| GB1142220A (en) | Skin treatment agent | |
| Seastone | The Effect of Sulfanilamide (Para-Amino-Benzenesulfonamide) on Group “C” Hemolytic Streptococcus Infections | |
| ES194506A1 (en) | IMPROVEMENTS MADE IN THE OBTAINING OF AUREOMYCIN PREPARATIONS | |
| ES323073A1 (en) | Coloring procedure blue. (Machine-translation by Google Translate, not legally binding) | |
| GB777018A (en) | Poliomyelitis vaccine products and methods for preparing the same | |
| FR2047886A1 (en) | Non-toxic anti-whooping cough vaccine | |
| GB1212886A (en) | Equine vaccine and vaccination treatment | |
| ES266340A1 (en) | PROCEDURE FOR THE PREPARATION OF POLYEMYELITIC VACCINES | |
| GB953992A (en) | Vaccine products and method of preparing same | |
| GB1184200A (en) | Improvements in or relating to the Treatment of Animal Tissue | |
| Murthy | Toxic Factor (s) in Vaccinia Virus and Its Neutralization by Penicillin. A Preliminary Communication | |
| GB898001A (en) | Therapeutic injectable iron preparations | |
| ES255146A3 (en) | Method of preparation of effective immunizing antigens in vaccination of cattle (Machine-translation by Google Translate, not legally binding) | |
| FR2174745A1 (en) | Mixed veterinary vaccine - active against symptomatic and bacterial anthrax | |
| ES266270A1 (en) | PROCEDURE FOR PREPARING POLYOMYELITIC VACCINES | |
| GB1229189A (en) | ||
| GB1235053A (en) | New organic acid and process for its preparation |